Members of the board of directors and executive management subscribe in ongoing rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, SOUTH AFRICA, CANADA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Biosergen AB (publ) (“Biosergen” or the “Company”) announces that CEO Peder Andersen, CFO Niels Laursen and board members Mattias Klintemar and Henrik Moltke are subscribing for a combined 58,522 units to a total value of 877,828 SEK in the ongoing rights issue of units (the “Rights Issue”).Subscription and underwriting